Re: 말초신경의 재생 한약 탐구 2021년...

[문형철]

Cells

. 2021 Aug 25;10(9):2194. doi: 10.3390/cells10092194

Therapeutic Potential of Complementary and Alternative Medicines in Peripheral Nerve Regeneration: A Systematic Review

Abstract

Despite the progressive advances, current standards of treatments for peripheral nerve injury do not guarantee complete recovery. Thus, alternative therapeutic interventions should be considered. Complementary and alternative medicines (CAMs) are widely explored for their therapeutic value, but their potential use in peripheral nerve regeneration is underappreciated. The present systematic review, designed according to guidelines of Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols, aims to present and discuss the current literature on the neuroregenerative potential of CAMs, focusing on plants or herbs, mushrooms, decoctions, and their respective natural products. The available literature on CAMs associated with peripheral nerve regeneration published up to 2020 were retrieved from PubMed, Scopus, and Web of Science.

According to current literature, the neuroregenerative potential of Achyranthes bidentata, Astragalus membranaceus, Curcuma longa, Panax ginseng, and Hericium erinaceus are the most widely studied. Various CAMs enhanced proliferation and migration of Schwann cells in vitro, primarily through activation of MAPK pathway and FGF-2 signaling, respectively. Animal studies demonstrated the ability of CAMs to promote peripheral nerve regeneration and functional recovery, which are partially associated with modulations of neurotrophic factors, pro-inflammatory cytokines, and anti-apoptotic signaling. This systematic review provides evidence for the potential use of CAMs in the management of peripheral nerve injury.

초록
점진적인 발전에도 불구하고 현재 말초 신경 손상에 대한 치료 표준은 완전한 회복을 보장하지 않습니다. 따라서 대체 치료 개입을 고려해야 합니다. 

보완대체의학(CAM)은 

그 치료적 가치에 대해 널리 연구되고 있지만 

말초신경 재생에 대한 잠재적 사용은 과소평가되고 있습니다. 

본 체계적 문헌고찰은 체계적 문헌고찰 및 메타분석 프로토콜의 우선 보고 항목 지침에 따라 설계되었으며, 식물 또는 허브, 버섯, 달인 및 각각의 천연물에 초점을 맞추어 CAM의 신경 재생 가능성에 대한 최신 문헌을 발표하고 논의하는 것을 목표로 합니다. 2020년까지 발표된 말초 신경 재생과 관련된 CAM에 관한 문헌은 PubMed, Scopus, Web of Science에서 검색했습니다. 

현재 문헌에 따르면, 

아키란테스 비덴타타(우슬), 황기, 커큐마 롱가(강황), 인삼, 헤리시움 에리나세우스(노루궁뎅이 버섯)의 

신경 재생 잠재력이 가장 널리 연구된 것으로 나타났습니다. 

Achyranthes bidentata, Astragalus membranaceus, Curcuma longa, Panax ginseng, and Hericium erinaceus

다양한 CAM은 시험관 내에서 

슈반 세포의 증식과 이동을 향상시키는데, 

주로 MAPK 경로와 FGF-2 신호의 활성화를 통해 이루어집니다. 

동물 연구에서는 

말초 신경 재생 및 기능 회복을 촉진하는 CAM의 능력이 입증되었으며, 

이는 부분적으로 신경 영양 인자, 전 염증성 사이토카인 및 항세포 사멸 신호의 조절과 관련이 있습니다. 

이 체계적인 검토는 말초 신경 손상 관리에서 CAM의 잠재적 사용에 대한 증거를 제공합니다.

Keywords: complementary and alternative medicines, natural products, peripheral nerve injury, nerve repair, nerve regeneration, functional recovery

1. Introduction

Peripheral nerve injury (PNI) can result in partial or total loss of motor, sensory and autonomic functions at denervated regions, leading to temporary or life-long disability [1]. In addition to reduced quality of life, functional deficits from PNI have a substantial economic impact on the affected individuals [2]. A recent study found that, over nine years (from 2009 to 2018), more than 550,000 individuals were afflicted by PNI in the United States. Moreover, the incidence rate has more than doubled throughout that period of time [3]. Such injuries are primarily due to vehicular and traumatic accidents, lacerations, and iatrogenic causes [4,5,6].

Despite progressive advances in our understanding of the processes and mechanisms of nerve injury, effective nerve repair and regeneration approaches that ensure complete functional recovery remain scarce [7]. Nerve autograft is considered the gold standard for repairing peripheral nerve defects [8]. However, this method is restricted by limited donor nerves and donor site morbidity, while successful recovery rates remain unsatisfactory [9]. Consequently, alternative strategies for enhancing nerve repairs have been proposed, including the application of nerve conduits and the addition of growth factors [10,11]. Likewise, the exploration of novel therapeutics, even combinatorial therapies, capable of enhancing axonal regeneration and promoting functional recovery, are of great interest.

PNI often results in neuropathic pain, and when conventional treatments are inadequate in providing relief, patients may turn to complementary and alternative medicines (CAMs), such as herbal medicines and nutritional supplements [12]. Indeed, medicinal plants, including the Acorus calamus [13], Curcuma longa [14], and Ginkgo biloba [15], have displayed ameliorating effects in animal models of neuropathic pain. Research on the potential of medicinal plants in the treatment of PNI is prompted by the notion that plants are great sources of natural products (NPs), which are small molecules produced by living organisms. Many NPs are the focus of drug development, as it is generally believed that they are largely devoid of adverse effects compared to synthetic drugs [16,17]. NPs also have the advantage of being evolutionary-driven, thus they are more likely to possess tremendous chemical and structural diversity that facilitates efficient engagement with biologically relevant targets and receptors, making them more biologically active [18]. In fact, many small-molecule drugs that have been approved by regulatory agencies were derived from natural sources [19], including Taxol from Taxus brevifolia [20] and Vinblastine from Catharanthus roseus [21].

However, compared to the extensive research on naturally derived products for other non-communicable and infectious diseases, NPs remain largely unexplored in the field of nerve repair and regeneration. A review published nearly half a decade ago has shed light on the neuroprotective effects of NPs in PNI models [22]. This review presents current research findings and eval‎uates the role of CAMs, focusing on plants or herbs, mushrooms, and decoctions, as well as their NPs, in peripheral nerve regeneration, to highlight their therapeutic potential for the management of PNI.

1. 소개

말초 신경 손상(PNI)은 신경이 손상된 부위의 운동, 감각 및 자율 기능의 부분적 또는 전체적 상실을 초래하여 일시적 또는 평생 장애를 초래할 수 있습니다 [1]. PNI로 인한 기능적 결손은 삶의 질 저하 외에도 영향을 받는 개인에게 상당한 경제적 영향을 미칩니다 [2]. 최근 연구에 따르면 2009년부터 2018년까지 9년 동안 미국에서는 55만 명 이상의 사람들이 PNI로 고통받고 있는 것으로 나타났습니다. 또한 같은 기간 동안 발병률은 두 배 이상 증가했습니다[3]. 이러한 부상은 주로 차량 및 외상성 사고, 열상 및 의인성 원인으로 인해 발생합니다 [4,5,6].

신경 손상의 과정과 메커니즘에 대한 이해가 점진적으로 발전하고 있음에도 불구하고 완전한 기능 회복을 보장하는 효과적인 신경 복구 및 재생 접근법은 여전히 부족합니다 [7]. 신경 자가 이식은 말초 신경 결손을 복구하기 위한 표준으로 간주됩니다 [8]. 그러나 이 방법은 제한된 기증자 신경과 기증자 부위 이환율로 인해 제한이 있으며 성공적인 회복률은 여전히 불만족스러운 수준입니다 [9]. 따라서 신경 도관을 적용하고 성장 인자를 추가하는 등 신경 복구를 향상시키기 위한 대체 전략이 제안되었습니다 [10,11]. 마찬가지로, 축삭 재생을 강화하고 기능 회복을 촉진할 수 있는 새로운 치료법, 심지어 병용 요법에 대한 탐색도 큰 관심을 끌고 있습니다.

PNI는 종종 신경병증성 통증을 유발하며, 기존 치료법으로 통증이 완화되지 않는 경우 환자는 한약 및 영양 보충제와 같은 보완 대체 의학(CAM)에 의지할 수 있습니다[12].

실제로 약용 식물인

아코러스 칼라무스(석창포) [13], 커큐마 롱가 [14], 은행나무 [15]는

신경병증성 통증의 동물 모델에서 개선 효과를 나타냈습니다.

 Acorus calamus [13], Curcuma longa [14], and Ginkgo biloba [15]

PNI 치료에서 약용 식물의 잠재력에 대한 연구는 식물이 살아있는 유기체가 생산하는 저분자 천연물(NP)의 훌륭한 공급원이라는 개념에서 촉발되었습니다. 일반적으로 합성 약물에 비해 부작용이 거의 없는 것으로 알려져 있기 때문에 많은 NP가 약물 개발의 초점이 되고 있습니다 [16,17]. 또한 NP는 진화에 의해 만들어졌기 때문에 생물학적으로 관련된 표적 및 수용체와 효율적으로 결합하여 생물학적 활성을 높일 수 있는 엄청난 화학적 및 구조적 다양성을 보유할 가능성이 높다는 장점이 있습니다[18]. 실제로 규제 기관의 승인을 받은 많은 저분자 약물이 천연물에서 유래되었으며[19], 여기에는 탁솔(Taxus brevifolia)[20]과 빈블라스틴(Catharanthus roseus)[21]이 포함됩니다.

그러나 다른 비전염성 및 전염성 질환에 대한 자연 유래 제품에 대한 광범위한 연구와 비교하면 신경 복구 및 재생 분야에서 NP는 아직 미개척 분야로 남아 있습니다. 거의 반세기 전에 발표된 한 리뷰에서는 PNI 모델에서 NP의 신경 보호 효과를 조명한 바 있습니다[22]. 이 리뷰에서는 최신 연구 결과를 제시하고 말초 신경 재생에 있어 식물 또는 허브, 버섯, 달인물과 그 NP에 초점을 맞춘 CAM의 역할을 평가하여 PNI 관리에 대한 치료 잠재력을 강조합니다.

2. Materials and Methods

This systematic review was designed according to guidelines of Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) [23].

2.1. Search Strategy and Data Extraction

A literature search was performed to find all relevant publications up to 25 October 2020 across three electronic databases, PubMed, Scopus, and Web of Science. The following keywords were used to search each respective database: ((“peripheral* nerve* regenera*” OR “peripheral* nerve* repair*” OR “neuroregenera*”) AND (“alga*” OR “seaweed*” OR “plant” OR “natural product*” OR “mushroom” OR “Basidiomycete*” OR “herb*” OR “Traditional Chinese Medicine*” OR “alternative medicine” OR “complementary medicine*”)).

2.2. Eligibility Criteria

Research articles describing the use of plants or herbs, mushrooms, algae, decoction, and their natural products in peripheral nerve repair and regeneration, written in English, and having full-text availability were considered. Articles not representing original research studies and NPs derived from sources other than plants, herbs, algae, and mushrooms were excluded (e.g., Lumbricus rubellus—earthworm). Retrieved articles were screened based on their title, abstract, and full-text to determine their eligibility for inclusion in this review.

3. Results

A preliminary search across the three databases yielded 560 records, of which 215 were duplicates (Figure 1). Together with 18 other records identified by other means, the remaining articles were screened based on the eligibility criteria, resulting in 289 additional records being excluded, leaving 56 records remaining and their findings being included in the qualitative synthesis (Figure 1). The studies investigated the neuroregenerative potential of 25 species of plants, three different mushrooms, and four traditional Chinese medicine decoctions, of which 18 known NPs were characterized. None of the studies investigated the potential of algae in peripheral nerve regeneration.

세 데이터베이스에서 예비 검색을 실시한 결과 560개의 기록이 나왔고, 이 중 215개가 중복되었습니다(그림 1). 다른 방법으로 확인된 18개의 다른 논문과 함께 나머지 논문을 적격성 기준에 따라 선별한 결과 289개의 논문이 추가로 제외되어 56개의 논문이 남았고 그 결과를 정성적 종합에 포함시켰습니다(그림 1).

이 연구에서는

25종의 식물,

3종의 버섯,

4종의 전통 한약 달임의 신경 재생 잠재력을 조사했으며,

이 중 18종의 알려진 NP를 특성화했습니다.

말초 신경 재생에 있어 해조류의 잠재력을 조사한 연구는 없었습니다.

Figure 1.

Open in a new tab

Flow diagram of the literature search procedure for the selection of studies up to 25 October 2020 on the use of plants, mushrooms, algae, decoctions, and their natural products (NPs) in peripheral nerve repair and regeneration. Only articles written in English, and having full-text availability were included. Articles not representing original research studies and NPs derived from sources other than plants, herbs, algae, and mushrooms were excluded.

Among the 58 records, the majority of the reported findings were from in vivo studies (38 records) that used mainly histological and electrophysiological eval‎uation to examine peripheral nerve regeneration in rat models of sciatic nerve injury (SNI). In contrast, 11 records were in vitro studies, which included reports of the promoting effects of plants, mushrooms, decoctions, and their natural products on the proliferation and migration of Schwann cells (SCs), and on neurite outgrowth in dorsal root ganglion (DRG) explants and neurons. Additionally, nine records included both in vitro and in vivo studies. In terms of the mechanisms of the biological effects, regulation of the mitogen-activated protein kinase (MAPK) pathway was reported to be highly involved across these studies.

58개의 기록 중 보고된 연구 결과의 대부분은 주로 조직학적 및 전기생리학적 평가를 사용하여 좌골 신경 손상(SNI) 쥐 모델에서 말초 신경 재생을 조사한 생체 내 연구(38개 기록)였습니다. 이와 대조적으로 식물, 버섯, 달인 및 그 천연물이 슈반 세포(SC)의 증식과 이동, 등근 신경절(DRG) 이식체와 뉴런의 신경세포 발생을 촉진하는 효과에 대한 보고가 포함된 11건의 체외 연구 기록이 있었습니다. 또한 시험관 내 연구와 생체 내 연구가 모두 포함된 9개의 기록이 있습니다. 생물학적 효과의 기전 측면에서 보면, 미토겐 활성화 단백질 키나아제(MAPK) 경로의 조절이 이러한 연구 전반에 걸쳐 크게 관여하는 것으로 보고되었습니다.

4. Discussion

4.1. Current Therapeutic Approaches against Peripheral Nerve Injuries

Peripheral nerves are prone to injury because of their delicate structures and superficial location throughout the human body. The preval‎ence of PNI together with its societal impact poses a health concern that needs to be addressed properly. Current treatment strategies for PNI are divided into surgical and non-surgical approaches that can be effective when applied appropriately [24]. Surgical techniques, including suturing of severed nerves and nerve grafting, do yield successful outcomes but are sometimes not feasible due to limitations such as the timing of surgery, size of nerve gaps, and donor site morbidity [25,26]. Consequently, other promising alternatives have emerged in recent years and have been receiving increasing attention, such as the utilization of different nerve conduits capable of housing and delivering biological cues whilst enhancing and guiding nerve regeneration 11, growth factor treatments [27], and cell-based therapies [28]. In contrast, non-surgical options for the management of PNI are far more limited, including approved medications on the market, electrical nerve stimulation [29], and the application of phytochemicals and secondary metabolites. The latter is widespread in other areas of research including cancer [30] and neurological disorders [31], but are far less preval‎ent in the field of peripheral nerve regeneration.

4. 토론

4.1. 말초 신경 손상에 대한 현재의 치료 접근법

말초 신경은 섬세한 구조와 인체 전체에 걸쳐 표면적으로 위치하기 때문에 부상을 입기 쉽습니다. PNI의 유병률과 사회적 영향은 적절한 대처가 필요한 건강 문제를 야기합니다. 현재 PNI의 치료 전략은 수술적 접근과 비수술적 접근으로 나뉘며, 적절히 적용하면 효과적일 수 있습니다 [24]. 절단된 신경 봉합 및 신경 이식을 포함한 수술적 기술은 성공적인 결과를 얻을 수 있지만 수술 시기, 신경 간격의 크기 및 기증자 부위 이환율과 같은 제한으로 인해 때때로 실현 가능하지 않습니다 [25,26]. 따라서 최근 몇 년 동안 신경 재생을 촉진하고 유도하면서 생물학적 신호를 수용하고 전달할 수 있는 다양한 신경 도관의 활용, 성장 인자 치료 [27], 세포 기반 치료 [28] 등 다른 유망한 대안이 등장하고 있으며 점점 더 많은 관심을 받고 있습니다. 반면, PNI 관리를 위한 비수술적 옵션은 시판 중인 승인된 약물, 전기 신경 자극[29], 식물성 화학물질 및 이차 대사물질의 적용 등 훨씬 더 제한적입니다. 후자는 암[30] 및 신경 장애[31] 등 다른 연구 분야에서는 널리 사용되고 있지만 말초 신경 재생 분야에서는 널리 보급되지 않았습니다.

4.2. Mechanisms of Peripheral Nerve Injury and Regeneration

Nerve bundles are primarily composed of axons covered with myelin sheaths produced by Schwann cells with fibroblasts scattered in between the nerve fibers. During peripheral nerve injury, instantaneous tissue damage occurs at the site of the lesion together with the accumulation of galectin-3 macrophages, whereas nerve stumps that are distally located undergo cellular variation despite not being directly affected [32]. After an axonal injury, Wallerian degeneration occurs, followed by axonal regeneration, and eventually end-organ reinnervation (see Figure 2) [33]. Wallerian degeneration takes place 24 to 48 h following nerve injury. Axons begin to disintegrate and growth factors such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) are released by SCs in the segment distal to the injured site. Galectin-3 macrophages are then recruited to the distal end, which contributes to myelin degradation and removal of remaining debris [34]. Growth factors are also retrogradely transported proximally toward the cell body. Subsequent removal of deteriorated myelin and axonal matter leads to the proliferation and alignment of SCs, forming the bands of Büngner that further guide the regenerating axons from the proximal to the distal site [35]. Axonal regeneration in humans is known to occur at a rate of approximately 1 mm per day [36], which would require months or even years for severe nerve injuries to fully recover. Moreover, poor functional recovery can occur due to a number of reasons, including progressive failure of axonal regeneration, disruption of SC function in providing a growth-supportive environment, and misdirection of regenerating axons [36].

4.2. 말초 신경 손상 및 재생 메커니즘

신경 다발은

주로 신경 섬유 사이에 섬유아세포가 흩어져 있는

슈반 세포에 의해 생성된 수초로 덮인 축삭으로 구성됩니다.

말초 신경 손상 시 병변 부위에서는

갈렉틴-3 대식세포의 축적과 함께

즉각적인 조직 손상이 발생하는 반면,

원위에 위치한 신경 그루터기는 직접적인 영향을 받지 않더라도 세포 변이를 겪습니다 [32].

축삭 손상 후 월러리안 변성이 일어나고

축삭 재생이 일어나고

결국 말단 장기 재신경화가 일어납니다( 그림 2 참조) [33].

왈러리아 변성은 신경 손상 후 24~48시간 후에 발생합니다.

축삭이 분해되기 시작하고

손상 부위 원위 세그먼트의 SC에서

신경 성장 인자(NGF)와 뇌 유래 신경 영양 인자(BDNF)와 같은 성장 인자가 방출됩니다.

그런 다음 갈렉틴-3 대식세포가

원위 말단에 모집되어 미엘린 분해와 잔여 잔해물 제거에 기여합니다 [34].

성장 인자는

또한 세포체를 향해 근위부로 역행적으로 운반됩니다.

이후 열화된 미엘린과 축삭 물질을 제거하면 SC가 증식하고 정렬되어

재생 축삭을 근위부에서 원위부까지 안내하는 뷩너 띠가 형성됩니다 [35].

인간의 축삭 재생은

하루에 약 1mm의 속도로 일어나는 것으로 알려져 있으며[36],

심각한 신경 손상이 완전히 회복되려면 수개월 또는 수년이 걸릴 수 있습니다.

또한,

축삭 재생의 점진적 실패,

성장 지원 환경을 제공하는 SC 기능의 중단,

재생 축삭의 잘못된 방향 등

여러 가지 이유로 인해 기능 회복이 제대로 이루어지지 않을 수 있습니다 [36].

Figure 2.

Open in a new tab

Overview of mechanism of peripheral nerve injury and regeneration. Following nerve injury, Wallerian degeneration occurs, in which axons begin to disintegrate at the distal end, and growth factors (such as NGF and BDNF) are released by Schwann cells. Galectin-3 macrophages are recruited to remove axonal debris and degrade myelin sheaths. Subsequently, SCs align to form the Band of Büngner, which guides the regenerating axons from the proximal to distal sites. Eventually, the regenerated axons innervate the end tissue to complete the recovery process. NGF—nerve growth factor; BDNF—brain-derived neurotrophic factor.

말초 신경 손상과 재생의 메커니즘 개요. 

신경 손상 후에는 

축삭이 말단에서 분해되기 시작하는 월러리안 변성이 일어나고, 

슈반 세포에서 성장 인자(NGF 및 BDNF 등)가 방출됩니다. 

갈렉틴-3 대식세포가 모집되어 

축삭 파편을 제거하고 미엘린 수초를 분해합니다. 

그 후 SC가 정렬하여 재생 축삭을 근위부에서 원위부로 안내하는 뷩너 밴드를 형성합니다. 

결국 

재생된 축삭은 

말단 조직에 신경을 공급하여 회복 과정을 완료합니다. 

NGF-신경 성장 인자; BDNF-뇌 유래 신경영양 인자.

4.3. Role of Schwann Cells in Nerve Regeneration

Schwann cells are supportive glial cells that are known to play a pivotal role in the proper functioning and maintenance of peripheral nerves. They are responsible for producing the basal lamina that determines the polarity of SCs and myelinating axons [37]. The myelin sheaths on axons allow the conduction of action potentials at high velocity via the formation of specialized nodes of Ranvier [38]. The high plasticity of SCs allows them to further develop into repair phenotypes in response to nerve injury (Figure 3). Following nerve injury, SCs can re-differentiate into repair SCs that align themselves to form bands of Büngner. This in turn allows axons to emerge from growth cones proximal to the injured site, which then elongate along the bands until the target organ is reinnervated. The repair SCs also participate in the removal of axon and myelin debris, and they can recruit macrophages to assist in the process [39]. In addition, repair SCs can also secrete neurotrophic factors that help promote cellular survival, proliferation, and differentiation, which are all essential for peripheral nerve repair [40]. Due to the importance of SCs in promoting peripheral nerve regeneration, it is expected that any disruption in SC proliferation, such as that caused by impairment in cyclin D1, will affect nerve regeneration following injury [41]. However, findings from past studies suggest that axonal regeneration is independent of SC proliferation [42,43]. Nevertheless, considering the association of SCs with axonal elongation and myelination, it is reasonable to hypothesize that enhanced SC proliferation may lead to greater regenerative potential. Hence, numerous studies have attempted to investigate the effects of NPs in promoting the proliferation and migration ability of SCs (Table 1).

4.3. 신경 재생에서 슈반 세포의 역할

슈반 세포는

말초 신경의 적절한 기능과 유지에 중추적인 역할을 하는 것으로 알려진 지지

신경교세포입니다.

이들은

SC와 수초 축삭의 극성을 결정하는

기저층을 생성하는 역할을 합니다[37].

축삭의 수초는

랜비에의 특수 노드 형성을 통해 활동 전위를 고속으로 전도할 수 있게 합니다 [38].

SC의 높은 가소성은

신경 손상에 대한 반응으로 복구 표현형으로

더욱 발전할 수 있게 합니다(그림 3).

신경 손상 후 SC는

스스로 정렬하여 뷩너 밴드를 형성하는 복구 SC로 재분화할 수 있습니다.

그러면 축삭이 손상된 부위 근위 성장 원뿔에서 나온 다음 대상 기관에 재신경이 공급될 때까지 밴드를 따라 늘어납니다. 복구 SC는 또한 축삭과 미엘린 파편의 제거에 참여하며, 이 과정을 돕기 위해 대식세포를 모집할 수 있습니다 [39]. 또한, 복구 SC는 말초 신경 복구에 필수적인 세포 생존, 증식 및 분화를 촉진하는 데 도움이 되는 신경 영양 인자를 분비할 수 있습니다 [40]. 말초 신경 재생을 촉진하는 데 있어 SC가 중요하기 때문에 사이클린 D1의 손상으로 인한 것과 같은 SC 증식 장애는 손상 후 신경 재생에 영향을 미칠 것으로 예상됩니다 [41]. 그러나 과거 연구 결과에 따르면 축삭 재생은 SC 증식과 무관한 것으로 나타났습니다 [42,43]. 그럼에도 불구하고 SC와 축삭신장 및 수초화의 연관성을 고려할 때, SC 증식이 강화되면 재생 잠재력이 더 커질 수 있다는 가설을 세우는 것이 합리적입니다. 따라서 수많은 연구에서 SC의 증식 및 이동 능력을 촉진하는 NP의 효과를 조사하려고 시도했습니다(표 1).

Figure 3.

Open in a new tab

Overview of Schwann cell plasticity and their roles following peripheral nerve injury. Immature SCs develop into either myelinated or non-myelinated forms depending on the type of axon association. Upon nerve injury, SCs are capable of converting into a repair phenotype alongside the demyelination process that is mediated by different genes and transcriptional mechanisms. These events promote neuronal survival and enhance axonal regeneration following injury. Subsequently, repair SCs can be reprogrammed back to remyelinate regenerated axons. Further details on SC plasticity are presented in the reviews by Jessen & Mirsky [39] and Nocera & Jacob [100]. BDNF—brain-derived neurotrophic factor; Erg2/Krox20—early growth response 2; ERK—extracellular signal-regulated protein kinase; GDNF—glial cell-derived neurotrophic factor; GFAP—glial fibrillary acidic protein; gpr126—adhesion G protein-coupled receptor G6; H3K27—methylation of histone H3 on lysine 27; HDAC2—histone deacetylase 2; IL—interleukin; L1—L1 cell adhesion molecule; LIF—leukemia inhibitory factor; Mag—myelin associated glycoprotein; Mbp—myelin basic protein; MCP-1—monocyte chemotactic protein 1; Mpz/P0—myelin protein zero; NCAM—neural cell adhesion molecule; NF2—neurofibromatosis 2; NGF—nerve growth factor; NT3—neurotrophin-3; Olig1—oligodendrocyte transcription factor 1; p75NTR—p75 neurotrophin receptor; Pmp22—peripheral myelin protein 22; SCs—Schwann cells; Shh—Sonic Hedgehog; Sox2—(sex determining region Y)-box 2; STAT3—signal transducer and activator of transcription 3; TGF-β—transforming growth factor-β; TLRs—Toll-like receptors; TNF-α—tumor necrosis factor-α; VEGF—vascular endothelial growth factor; Zeb2—zinc finger E-box-binding homeobox 2.

Table 1.

Summary of plants, mushrooms, and decoctions their natural products relating to peripheral nerve regeneration.

SourceMolecule(s)/IngredientsExperimental ModelEffective ConcentrationApplication MethodBiological

EffectMechanismReference

PLANT
Achyranthes bidentata	Polypeptides	In vitro (SCs isolated from the sciatic nerves of 1-day old SD rats)	0.1 µg/mL	Incubation	Promoted migration of SCs	Upregulation of NOX4/DUOX2-derived ROS production	[44]
	Polypeptides	In vitro (DRG explants harvested from spinal and peripheral roots of postnatal day 1 SD rats)	0.01, 0.1, 1 µg/mL (dose-dependent manner)	Incubation	Promoted neurite outgrowth from cultured DRG explants/neurons	Activation of ERK1/2	[45]
		In vivo (Adult New Zealand rabbits)	6.0 mg/kg	Intravenous injection	Enhanced nerve regeneration and functional restoration after crush injury to rabbit common peroneal nerve (increased CMAP, density, diameter and thickness of myelinated fibers, and number of motor neurons in anterior horn)	N/A
	Polypeptides (Fraction K)	In vitro (DRG explants harvested from spinal and peripheral roots of postnatal day 1 SD rats)	50, 250 ng/mL (dose-dependent manner)	Incubation	Promoted neurite outgrowth in DRG explant and neurons	Activation of ERK1/2	[46]
		In vivo (ICR mice)	10 mg/kg	Intravenous injection	Promoted peripheral nerve regeneration in mice after SNI (increased diameter and thickness of myelinated fibers, CSA of gastrocnemius muscle fibers, SFI, and CMAP)	N/A
	Polypeptides	In vivo (SD rats)	2 mg in 0.2 mL saline	Intraperitoneal injection	Promoted functional and histological recovery after rat sciatic nerve crush (increased SFI, CMAP, MNCV, myelin thickness, lamellae number, CSA of gastrocnemius muscle fibers)	Modulation of mRNA expression‎ of GAP-43, neurotrophic factors (NGF, BDNF, CNTF), and neurotrophic factor receptors (TrkA, TrkB)	[47]
	Polypeptides	In vivo (ICR mice)	1, 4, 16 mg/kg (dose-independent manner)	Tail vein injection	Promoted functional and histological recovery after rat sciatic nerve crush (increased SFI, CMAP, MNCV, number, and diameter of myelinated fibers, axon diameter, myelin thickness, lamellae number, CSA of gastrocnemius muscle fibers)	N/A	[48]
	Aqueous extract	In vivo (Adult New Zealand rabbits)	10, 20 mg/kg (dose-dependent manner)	Intravenous injection	Promoted peripheral nerve regeneration in the crushed common peroneal nerve in rabbits (increased CMAP, CSA of tibialis posterior muscle, number of regenerated myelinated nerve fibers, and motoneurons in anterior horn of the spinal cord)	N/A	[49]
Alpinate Oxyphyllae Fructus (Alpinia oxyphylla Miq)	Protocatechuic acid	In vitro (RSC96 SCs)	1 mM	Incubation	Promoted proliferation and survival of RSC96 SCs	Upregulation of IGF-1 and activation of PI3K/Akt signaling	[50]
	Aqueous extract	In vitro (RSC96 SCs)	Proliferation: 20, 60, 200 µg/mL (dose-independent manner Migration: 20–200 µg/mL (dose-dependent manner	Incubation	Promoted proliferation and migration of RSC96 SCs	Upregulation of PAs (uPA, tPA) and MMP2/9 mediated through the activation of MAPK pathway (ERK1/2, JNK, p38)	[51]
		In vivo (SD rats)	30, 60, 100, 150, 200 µg/mL (dose-independent manner)	Injection into a silicone rubber tube bridging a 15mm sciatic nerve defect	Promoted peripheral nerve regeneration in rats with SNI
Astragalus membranaceus	Astragaloside IV	In vivo (BALB/c mice)	2.5, 5, 10 mg/kg (dose-dependent manner)	Intraperitoneal injection	Promoted sciatic nerve regeneration and functional recovery in mice (increased number and diameter of myelinated nerve fibers, MNCV, CMAP)	Upregulation of GAP-43 expression‎	[52]
	Astragaloside IV	In vivo (SD rats)	50 µM	Injection into a silicone rubber tube bridging a 15mm sciatic nerve defect	Promoted peripheral nerve regeneration in rats with SNI (increased number of myelinated axons and CMAP)	N/A	[53]
	Extract	In vivo (SD rats)	3 g/kg in 0.01 M of PBS	Intragastric gavage	Promoted peripheral nerve regeneration in rats with SNI (increased MNCV and latency, fluorogold labeling in the DRG, mean axonal density, percentage of CGRP area ratio, and macrophage density)	Modulation of local growth factors (FGF, NGF, PDGF, TGF-β) and immunoregulatory factors (IL-1, IFN-γ)	[54]
	Aqueous extract	In vitro (RSC96 SCs)	Proliferation: 12.5, 125, 250, 500 µg/mL (optimal at 12.5 µg/mL) Migration: 1.25, 12.5, 125, 250, 500 µg/mL (optimal at 1.25 µg/mL)	Incubation	Promoted proliferation and migration of RSC96 SCs	Proliferation: Increased cyclin protein A, D1, and E via ERK and p38 signaling pathways Migration: Activation of FGF-2 signaling, leading to upregulation of uPA and downregulation of PAI-1	[55]
Centella asiatica	Hydro-ethanolic extract	In vivo (SD rats)	400 µg/mL	Nerve conduit developed using decellularized artery seeded with C. asiatca-neurodifferentiated mesenchymal stem cells bridging a 15mm sciatic nerve defect	Promoted nerve regeneration and functional restoration in rats with SNI (increased CMAP, latency, MNCV, confirmation of angiogenesis, increased MBP expression‎, and number of myelinated axons)	N/A	[56]
Citrus medica var. sarcodactylis	Aqueous extract	In vitro (RSC96 SCs)	0.85, 1.7, 2.55, 3.4, 4.25 µg/mL (dose-dependent manner)	Incubation	Promoted proliferation and migration of RSC96 SCs	Proliferation: Upregulation of cyclin A and B1 Migration: Activation of FGF-2 signaling, leading to the upregulation of uPA and MMP-9	[57]
Codonopsis pilosula	Aqueous extract	In vitro (RSC96 SCs)	20, 40, 60, 80, 100 µg/mL (dose-independent manner)	Incubation	Promoted proliferation and migration of RSC96 SCs	Proliferation: Enhanced IGF-I signaling pathway, cell cycle controlling protein expressions (cyclin A, D1, E) and MAPK pathway (ERK, p38) Migration: Stimulated FGF-2-uPA-MMP9 migration pathway	[58]
Crocus sativus	Crocin	In vivo (Wistar rats)	20, 80 mg/kg	Intraperitoneal injection	Promoted functional recovery in rats with SNI (Increased SFI, reduced plasma MDA levels, alleviated histological changes due to a crushing injury)	N/A	[59]
Curcuma longa	Alcoholic extract	In vivo (Wistar rats)	100 mg/kg (3, 6, or 9 times across 28 days)	Intraperitoneal injection	Protected against peripheral nerve degeneration in rats with SNI (Increased number of intact neurons in the right ventral horn of spinal cord region)	N/A	[60]
	Curcumin	In vivo (SD rats)	100 mg/kg (dissolved in olive oil)	Oral gavage	Promoted peripheral nerve regeneration in rats with SNI (increased mean cell volume, total volume and surface of DRG cells, total number, diameter, and area of myelinated nerve fibers)	N/A	[61]
	Curcumin	In vivo (SD rats)	100 mg/kg (dissolved in olive oil)	Oral gavage	Promoted functional recovery (improved SFI) and protective effect on DRG (increased volume and number of A- and B- cells, number of satellite cells) in rats with SNI	N/A	[62]
	Curcumin	In vivo (SD rats)	50, 100, 300 mg/kg	Intraperitoneal injection	Promoted peripheral nerve regeneration in rats with SNI (increased number of motoneurons, number and diameter of myelinated axons, SFI, MNCV, amplitude of CMAP, muscle fiber area and reduced latency of CMAP, mechanical withdrawal threshold, thermal withdrawal latency)	N/A	[63]
	Curcumin	In vitro (SCs isolated from S100β-DsRed transgenic mice)	0.04-1 µM (0.1 µM having the highest proliferative effect)	Incubation	Promoted proliferation and migration of SCs	Proliferation: Modulated by ERK and p38 kinase pathways	[64]
Curcuma longa (curcumin); from honeybees (propolis)	Curcumin, propolis	In vivo (Wistar rats)	Curcumin (100 mg/kg) Propolis (200 mg/kg)	Administration through a nasogastric tube	Promoted functional recovery in rats with SNI (Increased SFI and amplitude of CMAP, reduced latency time)	N/A	[65]
Dioscoreae rhizoma	Aqueous extract	In vivo (SD rats)	10 mg/mL	Applied directly into the crush site	Promoted peripheral nerve regeneration in rats with SNI (increased number of DRG sensory neurons and motor neurons in the spinal cord)	Increasing protein levels of GAP-43 and Cdc2	[66]
Epimedium	Icariin	In vivo (SD rats)	20 mg in 5 mL	Injection into a poly(lactic-co-glycolic acid) biological conduit sleeve bridging a 5mm sciatic nerve defect	Promoted peripheral nerve regeneration in rats with SNI (increased sciatic nerve conduction velocity and number of myelinated fibers)	N/A	[67]
	Epimedium extract, icariin	In vivo (SD rats)	4.873 mg/mL	Intragastric administration	Promoted peripheral nerve regeneration in rats with SNI (Increased SFI, nerve regeneration based on nerve pinch test, MNCV, muscle wet weight)	N/A	[68]
Gardenia jasminoides Ellis	Genipin	In vivo (SD rats)	3% aqueous gelatin solution fixed with 3% genipin	Injection into a silicone rubber tube bridging a 10mm sciatic nerve defect	Promoted peripheral nerve regeneration in rats with SNI	N/A	[69]
Gastrodia elata Blume	Gastrodin	In vitro (RSC96 SCs)	50, 100, 200 µM (dose-dependent manner)	Incubation	Promoted proliferation of RSC96 SCs in a dose- and time-dependent manner	Inhibition of ERK1/2 phosphorylation and activation of Akt phosphorylation	[70]
Ginkgo biloba	Ginkgo biloba extract (EGb 761)	In vivo (SD rats)	50 mg/kg	Intraperitoneal injection paired with an 18mm acellular nerve allograft bridging a 15mm sciatic nerve defect	Promoted peripheral nerve regeneration in rats with SNI (increased density of regenerated axons, muscle mass, axon number and diameter, expression‎ of CD34 and NF200)	Increasing expression‎ of angiogenesis-related genes (Vegf, Sox18, Prom1, IL-6)	[71]
	Ginkgo biloba extract (EGb 761)	In vitro (SCs isolated from spinal nerves of 1-day old SD rats)	1, 10, 20, 50, 100 µg/mL (dose-dependent manner)	Incubation	Promoted cell attachment and survival of SCs	N/A	[72]
		In vivo (SD rats)	10, 50 µg/mL	Injection into poly(DL-lactic acid-co-glycolic acid) conduit seeded with Schwann cells bridging a 12mm sciatic nerve defect	Promoted histological and functional recovery in rats with SNI (increased number and area of myelinated axons, increased CMAP)
Ginseng	Ginsenoside Rg1	In vitro (RSC96 SCs)	Ginseng: 100, 200, 300, 400, 500 µg/mL Ginsenoside: 5, 10, 15, 20, 25 µg/mL) (Dose-dependent manner for both)	Incubation	Promoted proliferation and migration of RSC96 SCs	Proliferation: Enhancing protein expression‎ of IGF-I pathway regulators (IGF-IR, PI3K, p-Akt, p-Bad, Bcl-2), cell cycle controlling proteins (cyclin D1, E, A), and MAPK signaling pathway (ERK, JNK, p38) Migration: Stimulating the FGF-2-uPA-MMP9 migrating pathway	[73]
	Ginsenoside Rg1	In vivo(SD rats)	1.5 mg/kg	Intraperitoneal injection	Promoted peripheral nerve regeneration in rats with SNI (increased number of motoneurons, number, and diameter of myelinated axons, SFI, MNCV, improved CMAP latency and amplitude, the increased average percentage of muscle fiber)	N/A	[74]
	Ginsenoside Re	In vitro (SCs isolated from sciatic nerves of 3-day old SD rats)	0.5 mg/mL	Incubation	Promoted proliferation and migration of SCs	Phosphorylation of ERK1/2 and JNK 1/2	[75]
		In vivo (SD rats)	2.0 mg/kg	Intraperitoneal injection	Promoted peripheral nerve regeneration in rats with SNI (increased SFI, TSI, PCNA expression‎ level, improved pathological changes due to crushing injury, GAP43, and S-100 expression‎)
Green tea	(-)-Epigallocatechin-3-gallate (EGCG)	In vivo (Wistar rats)	50 mg/kg	Intraperitoneal injection	Promoted functional recovery (improved outcomes of foot position, toe spreading, extensor postural thrust, hopping reflex, von Frey hair, Randall–Sellito, hotplate, and tail-flick tests), improved morphological recovery in skeletal muscle tissues muscles, and protection towards muscle fibers in rats with SNI	Protection of muscle fibers from cellular death through activation of an anti-apoptotic signaling pathway (modulation of Bax, Bcl-2, and p53 expression‎)	[76]
	(-)-Epigallocatechin-3-gallate (EGCG)	In vivo (Wistar rats)	50 mg/kg	Intraperitoneal injection	Promoted peripheral nerve regeneration in rats with SNI (improved nerve morphology and functional recovery assessed by foot position, extensor postural thrust test, and withdrawal reflex threshold)	Reversal of Bax, Bcl-2, and survivin mRNA expression‎ induced by sciatic nerve injury	[77]
Can be found in a wide variety of plants	Syringic acid	In vitro (RSC96 SCs)	600 µM	Incubation	Promoted proliferation and migration of RSC96 SCs	Downregulation of miR-451-5p	[78]
Can be found in a wide variety of plants	Ursolic acid	In vivo (BALB/c mice)	2.5, 5, 10 mg/kg (dose-dependent manner)	Intraperitoneal injection	Promoted peripheral nerve regeneration in rats with SNI (increased number and diameter of myelinated nerve fibers and soleus muscle mass)	Increasing S100 protein expression‎ levels	[79]
Lycium barbarum	Polysaccharide	In vitro (1) PC12 cells (2) Rat SCs (3) DRG neurons isolated from the embryo of 14-day pregnant rat	10, 30, 50 mg/mL (optimal at 30 mg/mL)	Incorporated into core-shell structured nanofibrous scaffolds by coaxial electrospinning	(1) Promoted proliferation and neuronal differentiation of PC12 cells (2) Promoted proliferation and myelination of SCs (3) Promoted neurite outgrowth of DRG neurons	N/A	[80]
Can be found in a wide variety of plants	Quercetin	In vitro (RSC96 SCs)	0.1, 1, 10 µg/mL	Incubation	Promoted proliferation of RSC96 SCs	N/A	[81]
		In vivo (SD rats)	0.1, 1, 10 µg/mL	Injection into a silicone rubber tube bridging a 15mm sciatic nerve defect	Promoted peripheral nerve regeneration in rats with SNI (increased count and density of myelinated axons, and resulted in larger area and amplitude of CMAP)
Morus sp.	Cortex Mori Radicis (aqueous extract)	In vivo (SD rats)	100 mg/kg	Gastrointestinal administration	Reduced blood glucose levels, improved nerve functions (thermal latency and mechanical threshold), reversed the loss of Nissl bodies and induced neurite outgrowth in DRG neurons, and restored the response of growth cones to NGF in diabetic rats	Neurite outgrowth: Increased expression‎ of TRPC1, reduced Ca2+ influx, and activation of PI3K/Akt signaling	[82]
Pueraria lobata	Puerarin	In vitro (RSC96 SCs)	1, 10, 100 µM (dose-independent manner)	Incubation	Promoted growth of SCs	N/A	[83]
		In vivo (SD rats)	1, 10, 100 µM (dose-independent manner)	Injection into a silicone rubber tube bridging a 15mm sciatic nerve defect	Promoted peripheral nerve regeneration in rats with SNI (increased density of myelinated axons, CMAP, and MNCV)
	Serum metabolites (obtained from rats fed with Pueraria lobata extract)	In vitro (PC12 cells)	0.01, 0.1, 1 unit	Incubation	Enhanced NGF-mediated neurite outgrowth and expression‎ of synapsin I in PC12 cells	N/A	[84]
		In vivo (SD rats)	0.01, 0.1, 1 unit	Injection into silicone rubber chamber bridging a 10mm sciatic nerve defect	Promoted peripheral nerve regeneration in rats with SNI (increased mean values of myelinated axon number, endoneurial area, and total nerve area)
Radix Hedysari	Aqueous extract	In vivo (SD rats)	1 g/mL	Oral gavage paired with biodegradable chitin conduit bridging a 2mm sciatic nerve defect	Promoted peripheral nerve regeneration in rats with SNI (increased MNCV, fiber and axon diameter, g-ratio)	N/A	[85]
	Polysaccharides	In vivo (SD rats)	0.25 g/mL	Oral gavage	Promoted peripheral nerve regeneration in rats with sciatic nerve defect (increased SFI, TFI, PFI values, MNCV, and number of regenerated myelinated nerve fibers)	N/A	[86]
Rhodiola rosea L.	Salidroside	In vivo (SD rats)	5, 10 mg/kg	Intraperitoneal injection	Promoted peripheral nerve regeneration in rats with SNI (increased number and diameter of myelinated axons, number of motoneurons, SFI, amplitude of CMAP, MNCV)	N/A	[87]
Scutellaria baicalensis Georgi	Baicalin	In vitro (RSC96 SCs)	5, 10, 20 µM (dose-dependent manner)	Incubation	Promoted proliferation of RSC96 SCs	Modulation of neurotrophic factors (GDNF, BDNF, CNTF) and S100β	[88]
Trigonella foenum-graecum (fenugreek)	IND01 (Fenugreek seed extract)	In vivo (Wistar rats)	50, 100, 200 mg/kg	Oral administration	Promoted peripheral nerve regeneration in rats with: (1) partial sciatic nerve ligation (ameliorated thermal hyperalgesia, improved motor function test scores) (2) SNI (ameliorated thermal hyperalgesia, improved motor function test scores, increased MNCV)	N/A	[89]
Tripterygium wilfordii Hook. F.	Triptolide	In vivo (SD rats)	100 µg/kg	Intraperitoneal injection	Promoted peripheral nerve regeneration in rats with SNI (increased number of motoneurons, number of myelinated axons, diameter of nerve fibers, SFI, CMAP amplitude, MNCV, muscle fiber area)	Reduction of TNF-α, IL-β, and IL-6 expression‎	[90]
MUSHROOM
Amanita muscaria	Muscimol	In vivo (SD rats)	400 μg/mL	Applied directly to the right L5 DRG	Promoted peripheral nerve regeneration in rats with SNI (prevented the development of thermal and mechanical hypersensitivity and mechanical allodynia, improved basal membrane integrity, and increased nerve fibers)	Normalization of PMP22 protein expression‎ level by GABAergic modulation in the ipsilateral DRG	[91]
Hericium erinaceus	Aqueous extract	In vivo (SD rats)	10 mL/kg	Oral administration	Promoted peripheral nerve regeneration in rats following peroneal nerve crush	Activation of signaling pathways (Akt, MAPK, c-Jun, c-Fos) and protein synthesis	[92]
	Polysaccharide	In vivo (SD rats)	30 mg/mL/kg	Oral administration	Promoted sensory functional recovery following peroneal nerve crush in rats (reduced withdrawal reflex latency)	Activation of Akt and p38 MAPK signaling and increased expression‎ of RECA-1	[93]
	Aqueous extract	In vivo (SD rats)	10, 20 mL/kg	Oral administration	Promoted peripheral nerve regeneration in rats following peroneal nerve crush (increased PFI, improved axon morphology, and development of neuromuscular junction)	N/A	[94]
Lignosus rhinocerotis	Aqueous extract	In vivo (SD rats)	500, 1000 mg/kg	Oral administration	Promoted motor and sensory functional recovery in rats with SNI (improved WRL and toe-spreading reflex)	N/A	[95]
DECOCTION
Bogijetong	(1) Bogijietong decoction (18 ingredients) (2) A reconstituted formulation of BGJTD (BeD) with 4 ingredients (3) Angelica gigas (an ingredient in BeD)	In vitro (Primary neurons isolated from DRG at lumbar levels 4 and 5 in adult rats)	400 mg/kg	Incubation	Promoted neurite outgrowth of DRG neurons	(1) BGJTD and BeD: Downregulation of TNF-α and p38, upregulation of p-ERK1/2; (2) Angelica gigas: Regulation of ERK1/2 activity and TNF-α production	[96]
		In vivo (SD rats and BALB/c mice)	400 mg/kg	Oral administration	Reduced latency time in rats
Buyang Huanwu	Buyang Huanwu decoction (16 ingredients: Modified formulation)	In vivo (SD rats)	1800 mg/kg	Oral administration paired with silicone rubber tube bridging a 10mm sciatic nerve defect	Promoted peripheral nerve regeneration in rats with sciatic nerve defect (increased nerve formation, myelinated axons, and endoneurial area)	N/A	[97]
Jiaweibugan	Jiaweibugan decoction (9 ingredients)	In vivo (Wistar rats)	28.6 g/kg	Intragastric administration	Protective effect on peripheral nerve injury by playing an anti-oxidative role in a diabetic rat model (increased MNCV and serum levels of glutathione, decreased serum levels of MDA)	Downregulation of NF-kB p65 and p38 MAPK mRNA expression‎	[98]
Qian-Zheng-San	Qian-Zheng-San (3 ingredients: Typhonii rhizoma, Bombyx batryticatus, Scorpio)	In vivo (SD rats)	1.75 g/mL	Oral gavage	Promoted peripheral nerve regeneration in rats with sciatic nerve defect (Increased SFI, MNCV, muscle wet weight, number of regenerated axons, axon diameter, nerve fiber diameter, myelin thickness, number of motor neurons in the lumbar spinal cord anterior horn)	N/A	[99]

Open in a new tab

Akt—protein kinase B; Bad—Bcl-2 associated agonist of cell death; Bax—Bcl-2-associated X protein; Bcl-2—B-cell lymphoma 2; BDNF—brain-derived neurotrophic factor; BGJTD—Bogijetong decoction; Cdc2—cell division cycle protein 2 homolog; CGRP—calcitonin gene-related peptide; CMAP—compound muscle action potential; CNTF—ciliary neurotrophic factor; CSA—cross-sectional area; DRG—dorsal root ganglion; DUOX2—dual oxidase 2; ERK—extracellular signal-regulated kinase; FGF—fibroblast growth factor; GABA—γ-aminobutyric acid; GAP-43—growth associated protein 43; GDNF—glial cell-derived neurotrophic factor; ICR mice—Institute of Cancer Research mice; IFN—interferon; IGF-1—insulin-like growth factor 1; IGF-IR—insulin-like growth factor 1 receptor; IL—interleukin; JNK—c-Jun N-terminal kinase; MAPK—mitogen-activated protein kinase; MBP—myelin basic protein; MDA—malondialdehyde; MMP—matrix metallopeptidase; MNCV—motor nerve conduction velocity; NF-κB—nuclear factor kappa B; NGF—nerve growth factor; NOX4—nicotinamide adenine dinucleotide phosphate oxidase 4; PAI-1—plasminogen activator inhibitor-1; PBS—phosphate buffered saline; PC12—pheochromocytoma cells; PCNA—proliferating cell nuclear antigen; PDGF—platelet-derived growth factor; PFI—peroneal nerve function index; PI3K—phosphoinositide 3-kinase; PMP22—peripheral myelin protein 22; Prom1—prominin 1; RECA-1—mouse monoclonal endothelial cell antibody; ROS—reactive oxygen species; RSC96 SC—RSC96 Schwann cell; SCs—Schwann cells; SD rats—Sprague-Dawley rats; SFI—sciatic function index; SNI—sciatic nerve injury; Sox18—sex-determining region Y-box transcription factor 18; TGF-β—transforming growth factor beta; TNF-α—tumor necrosis factor alpha; tPA—tissue plasminogen activator; Trk—tropomyosin receptor kinase; TRPC1—classical transient receptor potential 1; TSI—toe spread index; uPA—urokinase plasminogen activator; Vegf—vascular endothelial growth factor; WRL—withdrawal reflex latency.

4.4. Experimental Strategies and Neuroprotective Effects of Complementary and Alternative Medicines (CAMs) against Peripheral Nerve Injury

4.4.1. CAMs with Neuroregenerative Potential

Due to the limitations of conventional therapies for PNIs, much attention has been dedicated to finding alternative approaches in treating PNIs. To date, studies have explored the potential of 20 species of plants, three species of mushrooms, and four types of decoctions in promoting peripheral nerve regeneration (Table 1). Notably, the neuroregenerative potential of Achyranthes bidentata [44,45,46,47,48,49], Astragalus membranaceus [52,53,54,55], Curcuma longa [60,61,62,63,64,65], Panax ginseng [73,74,75], and Hericium erinaceus [92,93,94] have been most studied. A total of 18 natural products have been identified across the studies, and their chemical structures are shown in Table 2. Among those, ursolic acid, syringic acid, and quercetin are the NPs that can be found across a variety of plant species [78,79,81,101,102,103]. Decoctions are usually made according to traditional formulae. However, among the decoctions discussed in this study, the Bogijetong decoction is a relatively modern formulation that was specifically developed to treat neuropathic pain [96].

4.4. 말초신경 손상에 대한 보완대체의약품(CAM)의 실험적 전략 및 신경 보호 효과

4.4.1. 신경 재생 잠재력을 가진 보완대체의학(CAM)

PNI에 대한 기존 치료법의 한계로 인해 PNI 치료에 대한 대체 접근법을 찾는 데 많은 관심을 기울여 왔습니다.

현재까지

20종의 식물, 3종의 버섯, 4종의 달인 물이

말초 신경 재생을 촉진할 수 있는 잠재력을 탐색하는 연구가 진행되었습니다(표 1).

특히,

어성초[44,45,46,47,48,49],

황기[52,53,54,55],

강황[60,61,62,63,64,65],

인삼[73,74,75],

하수오[92,93,94]의 신경 재생 잠재력이 가장 많이 연구되어 왔습니다.

여러 연구를 통해 총 18개의 천연물이 확인되었으며, 그 화학 구조는 표 2 에 나와 있습니다. 그 중 우르솔산, 시린산, 케르세틴은 다양한 식물 종에서 발견되는 NP입니다 [78,79,81,101,102,103]. 달임은 일반적으로 전통적인 공식에 따라 만들어집니다. 그러나 본 연구에서 논의한 달인 중 보기제통 달인은 신경병증성 통증을 치료하기 위해 특별히 개발된 비교적 현대적인 제제입니다 [96].

4.4.2. In Vitro Studies on Neuroregenerative Potential of CAMs

Figure 4 summarizes the in vitro studies on neuroregenerative properties of complementary and alternative medicines. Most of the studies were in Schwann cells, with a few using DRG explants, neurons, and PC12 cells (rat pheochromocytoma). Some CAMs were reported to induce proliferation, differentiation, and neurite outgrowth in PC12 cells. Similarly, neurite outgrowth was also promoted in DRG neurons through modulation of the extracellular signal-regulated kinase (ERK), p38, and tumor necrosis factor-α (TNF-α). Polypeptides isolated from Achyranthes bidentata have demonstrated the ability to promote neurite outgrowth in DRG neurons through the activation of ERK1/2 [45,46]. These findings resemble an earlier study that also reported neurite growth in DRG neurons induced by CD95 through ERK activation [104]. The Bogijetong decoction and its reconstituted formulation BeD elicited similar neuroprotective effects through downregulation of p38 and TNF-α [96] It was previously shown that TNF-α could inhibit neurite outgrowth in cultured DRG neurons [105,106], whereas the application of a TNF-α antagonist supported axonal regeneration following nerve injury [107].

Figure 4.

Open in a new tab

Overview of in vitro studies that demonstrated the effects of natural products relating to peripheral nerve regeneration across different cell types with associated mechanisms. Akt—protein kinase B; Bad—Bcl-2 associated agonist of cell death; Bcl-2—B-cell lymphoma 2; BDNF—brain-derived neurotrophic factor; CNTF—ciliary neurotrophic factor; DRG—dorsal root ganglion; DUOX2—dual oxidase 2; ERK—extracellular signal-regulated kinase; FGF—fibroblast growth factor; GDNF—glial cell-derived neurotrophic factor; IGF-I—insulin-like growth factor 1; IGF-IR—insulin-like growth factor 1 receptor; JNK—c-Jun N-terminal kinase; MAPK—mitogen-activated protein kinase; MMP9—matrix metallopeptidase 9; NOX4—nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4; NPs—natural products; PC12—pheochromocytoma cells; PI3K—phosphoinositide 3-kinase; ROS—reactive oxygen species; S100β—S100 calcium-binding protein β; TNF-α—tumor necrosis factor-α; uPA—urokinase plasminogen activator.

Effects of CAMs on Schwann Cell Activity In Vitro

The studies examining the effects of complementary and alternative medicines and their related natural products on Schwann cells are primarily focused on promoting their proliferation and survival. The molecular mechanisms that were investigated in these studies include signaling pathways such as IGF-I and MAPK, as well as cell cycle controlling proteins and various neurotrophic factors (Figure 4). Past studies have demonstrated that ERK is required for proper myelination of SCs during development [108,109], and ERK signaling was rapidly activated following nerve injury, contributing to SC differentiation [110]. Moreover, evidence suggests that nerve regeneration following injury is closely associated with ERK [111,112], and ERK inhibition leads to impaired regenerative capability [111,113]. On the other hand, inhibition of p38 MAPK prevented SC demyelination and dedifferentiation, indicating its role in promoting the breakdown of myelin following nerve injury [114]. It is not unexpected that cyclins are associated with SC proliferation, as these proteins control cell cycle progression through the interaction of cyclin-dependent kinases. For instance, cyclin D is associated with Cdk4 or Cdk6 in the G1 phase, cyclin A participates with Cdk1 or Cdk2 in the S phase, cyclin E is involved with Cdk2 in G1 and S phases, cyclin B and Cdk1 regulates M phase [115,116].

Protocatechuic acid isolated from Alpinia oxyphylla Miq [50] and the aqueous extract of Codonopsis pilosula [58] were found to promote SCs proliferation by further enhancing IGF-I (insulin-like growth factor 1) signaling. The IGF-I growth factor is known to play a crucial role in neuromuscular recovery following injury. It is reported to be involved in promoting G1/S cell cycle progression [117] and survival of SCs [118] in vitro, and to facilitate peripheral nerve regeneration in vivo [119,120,121,122]. One study reported baicalin, a flavonoid that possesses various neuroprotective effects [123], induced proliferation of SCs through the modulation of neurotrophic factors including glial cell-derived neurotrophic factor (GDNF), BDNF, and ciliary neurotrophic factor (CTNF) [88]. These neurotrophic factors are integral to many aspects of nerve regeneration, as evident in past studies that showed their roles in myelin formation [124,125] and axonal regeneration [126,127].

In addition to promoting the proliferation of SCs, some NPs may promote the migratory ability of SCs, which is essential for regeneration and remyelination following nerve injury. Aqueous extracts of Alpinia oxyphylla Miq [51], Astragalus membranaceus [55], Citrus medica var. sarcodactylis [57], Codonopsis pilosula [58], and ginsenoside Rg1 isolated from ginseng [73] enhanced SC migration through the activation of FGF-2 signaling. The role of FGF-2 in the repair and regeneration of tissues [128] and its involvement in cell migration [129,130] is widely documented. A recently published study reported that another subfamily member, FGF5, is also involved in regulating SC migration and adhesion [131]. Besides FGF-2 signaling, another study investigating polypeptides of A. bidentata revealed that the upregulation of NOX4/DUOX2-derived reactive oxygen species (ROS) production was responsible for promoting SC migration [44]. Excessive accumulation of ROS production has been linked to neurodegenerative disorders [132] and peripheral neuropathy [133], but moderate levels of ROS may prove beneficial by acting as signal messengers in regulating biological processes, including cell adhesion and migration [134,135]. Syringic acid was shown to promote the proliferation and migration of SCs in vitro. Although the expression‎ of several microRNAs was affected by syringic acid, further analysis suggested that the plant polyphenol promoted SC proliferation and migration mainly by suppressing the microRNA miR-451-5p [78].

4.4.3. In Vivo Studies on Neuroregenerative Potential of CAMs

Current in vivo studies on the potential of complementary and alternative medicines in peripheral nerve regeneration are limited to rodent models (Figure 5 and Table 1). Most of the studies involved different strains of rats and mice, with only two studies using rabbits as their animal models. Models of peripheral nerve injury used in the studies include diabetic peripheral neuropathy, peroneal nerve injury, and sciatic nerve injury. The effects of CAMs on peripheral nerve regeneration were eval‎uated by functional recovery indexes (e.g., PFI; sciatic function index, SFI; tibial function index, TFI; CMAP; MNCV; and WRL) and histological examinations (e.g., number, diameter, the thickness of myelinated fibers and regenerated axons; the number of motoneurons; and muscle mass).

Figure 5.

Open in a new tab

Overview of in vivo studies that demonstrated the effects of natural products relating to peripheral nerve regeneration across different experimental models with associated mechanisms. Akt—protein kinase B; Bax—Bcl-2-associated X protein; Bcl-2—B-cell lymphoma 2; BDNF—brain-derived neurotrophic factor; Cdc2—cell division control protein; CGRP—calcitonin gene-related peptide; CMAP—compound muscle action potential; CNTF—ciliary neurotrophic factor; CSA—cross-sectional area; DRG—dorsal root ganglion; FGF—fibroblast growth factor; GAP-43—growth associated protein 43; ICR—Institute of Cancer Research; IFN-γ—interferon-γ; IL—interleukin; MAPK—mitogen-activated protein kinase; MBP—myelin basic protein; MDA—malondialdehyde; MMP2/9—matrix-metalloproteinase-2/9; MNCV—motor nerve conduction velocity; NF-κB—nuclear factor kappa B; NGF—nerve growth factor; NPs—natural products; PAs—plasminogen activators; PCNA—proliferating cell nuclear antigen; PDGF—platelet-derived growth factor; PFI—peroneal function index; PI3K—phosphoinositide 3-kinase; PMP22—peripheral myelin protein 22; Prom1—prominin 1; SD—Sprague-Dawley; SFI—sciatic function index; Sox18—sex-determining region Y-box transcription factor 18; TFI—tibial function index; TGF-β—transforming growth factor-β; TNF-α—tumor necrosis factor-α; tPA—tissue plasminogen activator; Trk—tropomyosin receptor kinase; TRPC1—transient receptor potential cation channel subfamily C member 1; TSI—toe spread index; uPA—urokinase plasminogen activator; Vegf—vascular endothelial growth factor; WRL—withdrawal reflex latency.

Diabetic Peripheral Neuropathy Model

In the diabetic neuropathy (DPN) model, aqueous extract of Cortex Mori Radicis had anti-diabetic and neuroregenerative effects, as evidenced by reduced blood glucose levels, induced neurite outgrowth, restoration of the loss of Nissl bodies, and a response in the growth cones of DRG neurons [82]. The authors identified that the observed effects were mediated by the activation of the PI3K/Akt pathway and increased expression‎ of TRPC1, which in turn reduced Ca2+ influx. The PI3K/Akt pathway is a crucial intracellular signaling pathway that governs cell proliferation, survival, and metabolism [136], its protective role against DPN has been previously hinted at [137,138]. The transient receptor potential (TRPC) is a family of Ca2+-permeable channels that participates in axonal regeneration [139]. In particular, TRPC1 and TRPC4 were shown to induce neurite outgrowth in PC12 cells and DRG neurons [140,141]. In another study, administration of Jiaweibugan decoction in a DPN model ameliorated changes in motor nerve conduction velocity (MNCV), and malondialdehyde (MDA), and glutathione levels through an anti-oxidative pathway via downregulating NF-κB p65 and p38 MAPK [98]. The activation of p38 MAPK, which belongs to a family of kinases that are responsive to stress stimuli, further activates NF-κB leading to inflammation, a driving factor of DPN [142,143].

Peroneal Nerve Injury Model

In the peroneal nerve injury model, aqueous extract and polypeptides of A. bidentata were shown to enhance nerve regeneration [45,49], as indicated by increased density and diameter of myelinated fibers, and numbers of motor neurons. Although behavioral analyses were not performed in the studies, improvements in compound muscle action potential (CAMP) demonstrated the ability of A. bidentata aqueous extract and polypeptides to promote functional recovery. Aqueous extract and polysaccharides from Hericium erinaceus also exhibited nerve regeneration and functional recovery following peroneal nerve crush [92,93,94], as evidenced by the improvements in the peroneal function index (PFI), withdrawal reflex latency (WRL) and axon morphology, and the development of neuromuscular junction. These findings were supported by the activation of Akt, p38, c-Jun, and c-Fos, which is in line with other studies that showed the importance of these signaling events for axonal regeneration [144,145,146].

Sciatic Nerve Injury Model

The sciatic nerve injury (SNI) model is the most commonly used model in the study of the effects of complementary and alternative medicines on peripheral nerve regeneration, and many studies have investigated the underlying mechanisms or molecular pathways through which CAMs elicit their neuroregenerative properties. For instance, polypeptides of A. bidentata [47], astragaloside IV isolated from A. membranaceus [52], and aqueous extract of Dioscoreae rhizoma [66] promoted nerve regeneration via upregulation of GAP-43 expression‎. The GAP-43 protein is highly associated with the development and plasticity of the nervous system [147]. Its expression‎ is known to be elevated following nerve injury [148] and is involved in the neurite outgrowth of hippocampal neurons [149]. Similarly, modulation of other neurotrophic factors such as NGF, BDNF, CNTF [47,54], and pro-inflammatory cytokines including IL-1, IL-6, IL-β, and TNF-α [54,90] were also involved in promoting nerve regeneration as well. Although an inflammatory response following injury is necessary for the regenerative process [150], prolonged inflammation can impede recovery and may even lead to the development of neuropathic pain [151], which reflects the double-edged property of inflammation and the importance of proper regulation. Additionally, a study on Ginkgo biloba extract showed that it promoted axonal angiogenesis through the modulation of related genes, including Vegf, Sox18, Prom1, and IL-6 [71]. Studies have also demonstrated the participation of Vegf [152,153], Prom1 [154], and another subfamily gene, Sox11 in sciatic nerve regeneration [155], and the restorative role of IL-6 has also been implied in DPN and central nervous system models [156,157]. Muscimol prevented hyperalgesia through the modulation of PMP22 [91], a key component of the basal lamina. The expression‎ of PMP22 is correlated with myelin formation and nerve regeneration [158,159]. Studies investigating EGCG in an SNI model showed that it had neuroprotective and regenerative effects, partly due to the modulation of the apoptotic machinery, including Bax, Bcl-2, p53, and survivin [76,77]. The subsequent loss of neurons after PNI is known to be closely related to apoptosis [160] which is partly influenced by p53 and Bax [161], while the association of survivin in nerve injury has also been documented [162].

좌골 신경 손상 모델

좌골 신경 손상(SNI) 모델은 보완 대체 의학이 말초 신경 재생에 미치는 영향을 연구하는 데 가장 일반적으로 사용되는 모델이며, 많은 연구에서 CAM이 신경 재생 특성을 이끌어내는 근본적인 메커니즘 또는 분자 경로를 조사했습니다. 예를 들어, A. 비덴타타의 폴리펩타이드[47], A. 멤브레나세우스에서 분리한 아스트라갈로사이드 IV[52], 디오스코레아 뿌리줄기의 수성 추출물[66]은 GAP-43 발현의 상향조절을 통해 신경 재생을 촉진했습니다. GAP-43 단백질은 신경계의 발달 및 가소성과 밀접한 관련이 있습니다 [147]. 이 단백질은 신경 손상 후 발현이 증가하는 것으로 알려져 있으며[148], 해마 신경세포의 신경돌기 성장에 관여합니다[149]. 마찬가지로, NGF, BDNF, CNTF [47,54] 및 IL-1, IL-6, IL-β 및 TNF-α [54,90] 같은 다른 신경 영양 인자의 조절도 신경 재생을 촉진하는 데 관여합니다. 손상 후 염증 반응은 재생 과정에 필요하지만[150], 장기간의 염증은 회복을 방해하고 심지어 신경 병증성 통증으로 이어질 수 있습니다[151], 이는 염증의 양날의 속성과 적절한 조절의 중요성을 반영합니다. 또한 은행잎 추출물에 대한 연구에 따르면 은행잎 추출물은 Vegf, Sox18, Prom1 및 IL-6를 포함한 관련 유전자의 조절을 통해 축삭 혈관 신생을 촉진하는 것으로 나타났습니다 [71]. 연구 결과에 따르면 좌골 신경 재생에 Vegf [152,153], Prom1 [154] 및 또 다른 하위 계열 유전자 인 Sox11이 참여하며 [155], IL-6의 회복 역할은 DPN 및 중추 신경계 모델에서도 암시되었습니다 [156,157]. 무시몰은 기저층의 핵심 구성 요소인 PMP22 [91]의 조절을 통해 통각 과민증을 예방했습니다. PMP22의 발현은 미엘린 형성 및 신경 재생과 상관관계가 있습니다 [158,159]. SNI 모델에서 EGCG를 조사한 연구에 따르면 부분적으로는 Bax, Bcl-2, p53, 서바이빈을 포함한 세포 사멸 메커니즘의 조절로 인해 신경 보호 및 재생 효과가 있는 것으로 나타났습니다 [76,77]. PNI 후 뉴런의 후속 손실은 세포 사멸과 밀접한 관련이 있는 것으로 알려져 있으며 [160] 이는 부분적으로 p53 및 Bax의 영향을 받으며 [161], 신경 손상에서 서바이빈의 연관성도 문서화되어 있습니다 [162].

4.4.4. Involvement of CAMs in Combinatorial Approaches for the Treatment of PNI

There is increasing evidence that the successful repair and regeneration of nerves will require not just a single treatment strategy, but a multifaceted strategy involving different disciplines. Studies adopting combinatorial approaches have yielded interesting findings. For example, Lycium barbarum polysaccharide incorporated into core-shell structured nanofibrous scaffolds by coaxial electrospinning showed proliferative effects in PC12, SCs, and DRG neurons [80]. In two separate studies, puerarin, the active component extracted from Pueraria lobata roots, as well as rat serum metabolites of P. lobata enhanced the neuroregenerative effects of silicone rubber nerve chambers. Increases in myelinated axons and structurally mature regenerated axons were observed, while muscle reinnervation led to functional recovery, as indicated by an increase in action potential and nerve conduction [83,84]. Similar results were obtained with Buyang Huanwu decoction being administered as a co-treatment alongside silicone rubber nerve chambers, which led to more prominent axonal regeneration [97]. In an SNI model, a magnetic nanocomposite scaffold produced from using magnetic nanoparticles and biodegradable chitosan-glycerophosphate polymer enhanced SC viability, nerve regeneration, and functional recovery when paired with an applied magnetic field [163]. The use of nerve guiding conduits gained popularity over the years. They have been used to isolate regenerating axons from fibrotic tissues, to protect them from mechanical forces, and to guide new-forming tissue as well as condensing growth factors secreted by SCs [164]. The concept was initiated with a simple hollow design but has since advanced to innovative ways of redesigning nerve conduits to further extend their original capabilities 11. The attractive characteristics of modern nerve conduits offer tremendous potentials. These nerve conduits are occasionally paired with other strategies for improving nerve outcomes. For instance, Chang et al. [165] developed a natural biodegradable multi-channeled scaffold with aligned electrospun nanofibers and a neurotrophic gradient, which resulted in superior nerve recovery and less muscle atrophy compared with nerve autografts. Hussin et al. [56] used Centella asiatica (L.) to neurodifferentiate mesenchymal stem cells. This was subsequently developed with decellularized artery as a nerve conduit, which demonstrated functional restoration in an SNI model similar to that of reversed autograft.

4.4.4. PNI 치료를 위한 복합적 접근법에 CAM의 참여

신경의 성공적인 복구와 재생을 위해서는 단일 치료 전략뿐만 아니라 다양한 분야를 포함하는 다각적인 전략이 필요하다는 증거가 점점 더 많아지고 있습니다. 복합적인 접근 방식을 채택한 연구들은 흥미로운 결과를 도출했습니다. 예를 들어, 동축 전기방사를 통해 코어-쉘 구조의 나노섬유 스캐폴드에 통합된 리시움 바바룸 다당류는 PC12, SC 및 DRG 뉴런에서 증식 효과를 보였습니다 [80]. 두 개의 개별 연구에서 푸에라리아 로바타 뿌리에서 추출한 활성 성분인 푸에라린과 P. 로바타의 쥐 혈청 대사산물이 실리콘 고무 신경 챔버의 신경 재생 효과를 향상시켰습니다. 골수화 된 축삭과 구조적으로 성숙한 재생 축삭의 증가가 관찰되었으며, 근육 재 신경화는 활동 전위와 신경 전도의 증가로 표시된 것처럼 기능 회복으로 이어졌습니다 [83,84]. 실리콘 고무 신경 챔버와 함께 부양 환우 달인을 병용 치료로 투여했을 때 유사한 결과를 얻었으며, 이는 더 두드러진 축삭 재생으로 이어졌습니다 [97].

SNI 모델에서 자성 나노 입자와 생분해성 키토산-글리세로인산 폴리머를 사용하여 제작한 자성 나노 복합 스캐폴드는 적용된 자기장과 결합되었을 때 SC 생존력, 신경 재생 및 기능 회복을 향상시켰습니다 [163]. 신경 유도 도관의 사용은 수년에 걸쳐 인기를 얻었습니다. 이 도관은 재생 축삭을 섬유화 조직으로부터 분리하고, 기계적 힘으로부터 보호하며, 새로 형성되는 조직과 SC에서 분비되는 응축 성장 인자를 유도하는 데 사용되었습니다 [164]. 이 개념은 단순한 속이 빈 디자인으로 시작되었지만 이후 신경 도관을 재설계하는 혁신적인 방법으로 발전하여 원래의 기능을 더욱 확장했습니다 11. 현대 신경 도관의 매력적인 특성은 엄청난 잠재력을 제공합니다. 이러한 신경 도관은 때때로 신경 결과를 개선하기 위한 다른 전략과 결합되기도 합니다. 예를 들어, Chang 등[165]은 전기방사 나노섬유와 신경 영양 구배를 정렬한 자연 생분해성 다중 채널 스캐폴드를 개발하여 신경 자가이식에 비해 우수한 신경 회복과 적은 근육 위축을 가져왔습니다. 후신 등[56]은 센텔라아시아티카(병풀)를 사용하여 중간엽 줄기세포를 신경 분화시켰습니다. 이후 탈세포화된 동맥을 신경 도관으로 사용하여 역 자가이식과 유사한 SNI 모델에서 기능 회복을 입증했습니다.

4.5. Limitations and Future Prospects

As mentioned earlier, PNI represents a significant health issue while the effectiveness of current treatment approaches is highly subjective. Hence, substantial effort is required to discover and establish proper methods for the management of PNI. Present studies have shown promising findings in utilizing various applications including nerve conduits [166], stem cell therapy [167], phytochemicals [22], and electrical stimulation [168] for treating PNI, and their potential may subsequently be improved when paired together. Evidence from in vitro and in vivo studies have delineated the neuroregenerative properties of various CAMs, and the underlying mechanisms have been investigated (as summarized in Figure 6), although they still remain incompletely understood and require further elucidation. Subsequently, pre-clinical and clinical studies on existing potential candidates and approaches should be supported to drive the development of future therapeutics.

Figure 6.

Open in a new tab

Summary of the molecular mechanisms associated with the neuroregenerative effects of CAMs. Vegf—vascular endothelial growth factor; Sox18—sex-determining region Y-box transcription factor 18; Prom1—prominin 1; IL—interleukin; IFN-γ—interferon-γ; Bax—Bcl-2-associated X protein; Bcl-2—B-cell lymphoma 2; Trk—tropomyosin receptor kinase; PMP22—peripheral myelin protein 22; FGF—fibroblast growth factor; NGF—nerve growth factor; PDGF—platelet-derived growth factor; TGF-β—transforming growth factor-β; NF-κB—nuclear factor kappa B; MAPK—mitogen-activated protein kinase; PI3K—phosphoinositide 3-kinase; Akt—protein kinase B; BDNF—brain-derived neurotrophic factor; CNTF—ciliary neurotrophic factor; TNF-α—tumor necrosis factor-α; TRPC1—transient receptor potential cation channel subfamily C member 1; GAP-43—growth-associated protein 43; PAI-1—plasminogen activator inhibitor-1; MMP2/9—matrix-metalloproteinase-2/9; tPA—tissue plasminogen activator; uPA—urokinase plasminogen activator.

Existing studies on the effect of complementary medicines in treating PNI are preliminary findings with limited information (Table 1). The majority of studies investigated crude extracts or specific fractions of extracts, with only 24 out of the 56 studies managing to identify the exact NPs responsible for the observed effects. Additionally, 25 studies did not report the underlying mechanisms for the resultant effects of NPs, especially at the in vivo stage. This situation highlights the need for greater efforts among the scientific community to fully investigate the purported effects of NPs. Another issue is the route and method of administration in vivo. It is known that oral administration is generally economical and relatively safe, but the resultant efficacy may not be reliable due to uncontrollable animal habits and behaviors [169]. In contrast, gavage or injection routes typically require some form of restraint, which may result in animal stress that may influence study outcomes. The administration routine also varied across studies, with the treatments lasting from a few days to months. Moreover, treatment frequency also influences experimental outcomes. Although it is difficult to standardize animal handling procedures, these factors should be taken into account with carefully designed studies.

In this review, the majority of studies on NPs as a treatment for PNI were based on plants and herbs, with a few studies on mushrooms such as Amanita muscaria, Hericium erinaceus, and Lignosus rhinocerotis, as well as some decoctions. This is unsurprising, considering that phytochemicals are highly studied for drug development, which should shed more light on this area of research [170,171,172]. However, the use of NPs for peripheral nerve repair and regeneration is still largely overlooked and could be an untapped potential source for promising drug candidates. For instance, a previous study demonstrated that various mushrooms including Agaricus blazei Murrill, Antrodia cinnamomea, Ganoderma lucidum, and Hirsutella sinensis could activate intracellular signaling kinases ERK, JNK, and p38, which are associated with peripheral nerve regeneration [173]. Another study showed that G. lucidum, Ganoderma neo-japonicum, and Grifola frondosa promoted neuritogenesis via the involvement of the MAPK signaling pathway [174]. Aside from exploring untapped sources of NPs, future research may also simultaneously examine the efficiency of CAMs or NPs with known neuroregenerative properties to compare their ability to promote regeneration of peripheral nerves.

The use of algae in peripheral nerve regeneration merits attention. Algae are well-known for their diverse applications in food nutrition [175], biofuels [176], cosmetics [177], and pharmaceuticals [178,179]. Recent studies have also demonstrated that algae could have potential in the treatment of neurological disorders, including Parkinson’s and Alzheimer’s disease [180,181]. However, the potential uses of algae in peripheral nerve regeneration have yet to be explored, despite evidence showing the ability of macroalgae to promote neurite outgrowth in hippocampal neurons [182,183,184]. More recently, a study showed that Gracilaria manilaensis induced the proliferation of neurite-bearing cells in the rat pheochromocytoma cell line, which is believed to mimic the neuroactivity of NGF [185]. Thus, investigation on the nerve regenerative potential of other NPs holds much promise.

5. Conclusions

Peripheral nerve injury remains a challenge, while future prospects are leaning towards multi-combinatorial approaches. Natural products are highly appreciated for their therapeutic value, and there is a growing body of evidence in their potential for peripheral nerve regeneration. The present findings showed that various NPs promote the proliferation and migration of SCs, most commonly through the activation of MAPK and FGF-2 signaling pathways, respectively. Promotion of peripheral nerve regeneration was also observed in rodent models, partly through the modulation of neurotrophic factors, pro-inflammatory cytokines, and anti-apoptotic signaling. Hence, NPs could play key roles in nerve repair and regeneration in the near future, especially when paired with other innovative approaches such as modern nerve conduits.

Acknowledgments

The authors are thankful to Sunway University for providing the necessary internet and library facilities for literature searching.

Author Contributions

Conceptualization, Y.-Y.Y., K.-H.W. and L.-W.L.; data curation, Y.-Y.Y., T.-K.G. and writing—original draft preparation, Y.-Y.Y., T.-K.G. and K.-Y.N.; review and editing, Y.-Y.Y., K.-Y.N., K.-H.W., L.-W.L., S.-M.P., S.-H.L. and S.R.; supervision, Y.-Y.Y., K.-H.W. and L.-W.L.; project administration, Y.-Y.Y. and K.-H.W.; funding acquisition, Y.-Y.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This work was funded by Fundamental Research Grant Scheme FRGS/1/2019/STG05/SYUC/02/1 from the Ministry of Higher Education Malaysia.

Conflicts of Interest

The authors declare no conflict of interest.

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

• 1.Navarro X. Functional eval‎uation of peripheral nerve regeneration and target reinnervation in animal models: A critical overview. Eur. J. Neurosci. 2016;43:271–286. doi: 10.1111/ejn.13033. [DOI] [PubMed] [Google Scholar]
• 2.Wojtkiewicz D.M., Saunders J., Domeshek L., Novak C.B., Kaskutas V., Mackinnon S.E. Social impact of peripheral nerve injuries. Hand. 2015;10:161–167. doi: 10.1007/s11552-014-9692-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 3.Li N.Y., Onor G.I., Lemme N.J., Gil J.A. Epidemiology of peripheral nerve injuries in sports, exercise, and recreation in the United States, 2009–2018. Phys. Sportsmed. 2020;49:1–8. doi: 10.1080/00913847.2020.1850151. [DOI] [PubMed] [Google Scholar]
• 4.Scholz T., Krichevsky A., Sumarto A., Jaffurs D., Wirth G.A., Paydar K., Evans G.R.D. Peripheral nerve injuries: An international survey of current treatments and future perspectives. J. Reconstr. Microsurg. 2009;25:339–344. doi: 10.1055/s-0029-1215529. [DOI] [PubMed] [Google Scholar]